HONG KONG, Feb. 26, 2026 /PRNewswire/ -- Taboola today announced the expansion of its leadership team with the hiring of Krishan Bhatia as Chief Business Officer.
Bhatia will lead global sales and partnerships for Taboola, with a focus on driving revenue growth across Taboola's entire product portfolio, which includes its Realize performance advertising platform, network of publisher partnerships, CTV performance, generative AI products and more. He joins with a formidable track record of accelerating growth for category-defining technology and media companies such as Amazon and NBCUniversal.
Most recently, Bhatia launched and led Amazon's global video advertising business across Prime Video, Live Sports, Twitch, and third-party programmers, serving as VP, Global Video Advertising and Partnerships. Before Amazon, Bhatia was President and Chief Business Officer of NBCUniversal's Global Advertising and Partnerships division where he oversaw the company's digital, streaming TV and advanced advertising business.
"Krishan is joining Taboola at a pivotal moment in our journey," said Adam Singolda, CEO of Taboola. "We are redefining performance advertising on the open web and beyond. Realize is gaining real momentum as advertisers look for scalable growth beyond search and social. At the same time, DeeperDive is bringing generative AI directly to publishers in ways that are helping them innovate and thrive. The opportunity in front of us is massive."
"Krishan has helped build and scale some of the most important advertising businesses in the world at Amazon and NBCUniversal," continued Singolda. "He understands how to operate at scale, how to partner with brands and agencies, and how to execute with discipline. We've spent years building a powerful foundation for long term success, surpassing two billion dollars in revenue under the strong leadership of Eldad Maniv, our President and COO. With that momentum, I'm excited to welcome Krishan Bhatia to the team as our first Chief Business Officer and for what he will bring as we scale the company and take our go to market execution to the next level."
"Taboola has a bold vision for the future, built on global scale and innovative technology to become a powerhouse for performance advertising and publisher success," said Krishan Bhatia, Chief Business Officer at Taboola. "Over the past year, Taboola has hit exciting milestones. The introduction of Realize further solidifies Taboola's place as the leading player in performance advertising outside of search and social. Taboola's launch of DeeperDive, pace of innovation with generative AI, and continued commitment to drive success for advertisers and partners are strong signals that today's market demands. I'm excited to come onboard at this pivotal point of growth for Taboola and to work alongside the entire team."
About Taboola:
Taboola empowers businesses to grow through performance advertising technology that goes beyond search and social and delivers measurable outcomes at scale. Taboola works with thousands of businesses who advertise directly on Realize, Taboola's powerful ad platform, reaching approximately 600M daily active users across some of the best publishers in the world. Publishers like NBC News, Yahoo, and OEMs such as Samsung, Xiaomi and others use Taboola's technology to grow audience and revenue, enabling Realize to offer unique data, specialised algorithms, and unmatched scale.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Taboola Names Krishan Bhatia as Chief Business Officer; Amazon Ads and NBCUniversal Veteran to Lead Global Sales and Partnerships
|
LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety.
Why Antibody Therapies Fail in Late-Stage Testing
Antibody therapies work in part by binding to Fcγ receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflammation. Since these receptors are different between species, human therapies tested in standard laboratory mice give unreliable efficacy results or miss potential safety risks. These discrepancies cause expensive late-stage failures and slow patient access to new therapies.
A New Mouse Model with Humanized Fcγ Receptors Set to Become a Gamechanger
A new study published in Science Immunology showed that an innovative mouse model developed by genOway, genO-hFcγR, helps scientists better predict the efficacy and safety of therapeutic antibodies in humans. The model allows scientists to rank different antibody candidates by how they are likely to perform, measure how effectively they target specific immune cells, and evaluate their potential to slow disease progression. This gives researchers key early insights to guide decisions and accelerate drug development.
Video on genO-hFcγR mice: https://www.youtube.com/watch?v=H7xO-xGJV8Q
Read the publication: https://www.science.org/doi/10.1126/sciimmunol.ady7328
A Complex Scientific Challenge Achieved Through International Collaboration
Due to the species-specific nature of Fcγ receptors, developing this model demanded multidisciplinary expertise in mouse genetics, antibody biology, and human immunology.
The achievement was made possible through an international consortium of leading biopharmaceutical partners, led by genOway, who combined their knowledge to co-develop and co-validate the genO-hFcγR mouse model. Consortium members included genOway (France), a company specializing in developing highly predictive preclinical models; argenx (Belgium), a pioneer in Fc-engineering and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University (Belgium), a leading immunology institute, to publish the study in Science Immunology. In this study, scientists at VIB-Ghent University mapped Fc receptor expression and regulation to illustrate how the new mouse model could be used to better model human disease and coordinated the publication of the work.
A Unique Solution Available for the Scientific Community
The genO–hFcγR model builds on a previous mouse model developed in 2008 by genOway and its scientific partners, in which multiple FcγR genes were humanized. Since its launch to the scientific community in 2024, genO-hFcγR has been adopted to advance preclinical programs of biopharmaceutical companies and nonprofit organizations, including the Gates Foundation, as one of the foundation's global health research initiatives.
Read the Gates Foundation press release at https://www.genoway.com/news-events/genoway-gates-foundation-2025
About genOway
genOway is a biotechnology company that provides highly predictive preclinical models and solutions to biopharmaceutical companies, CROs and academic institutions to bridge the gap between preclinical findings and clinical success. More information at genoway.com.
Contact
Ana REZA
Marketing Communications Manager
reza@genoway.com
LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety.
Why Antibody Therapies Fail in Late-Stage Testing
Antibody therapies work in part by binding to Fcγ receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflammation. Since these receptors are different between species, human therapies tested in standard laboratory mice give unreliable efficacy results or miss potential safety risks. These discrepancies cause expensive late-stage failures and slow patient access to new therapies.
A New Mouse Model with Humanized Fcγ Receptors Set to Become a Gamechanger
A new study published in Science Immunology showed that an innovative mouse model developed by genOway, genO-hFcγR, helps scientists better predict the efficacy and safety of therapeutic antibodies in humans. The model allows scientists to rank different antibody candidates by how they are likely to perform, measure how effectively they target specific immune cells, and evaluate their potential to slow disease progression. This gives researchers key early insights to guide decisions and accelerate drug development.
Video on genO-hFcγR mice: https://www.youtube.com/watch?v=H7xO-xGJV8Q
Read the publication: https://www.science.org/doi/10.1126/sciimmunol.ady7328
A Complex Scientific Challenge Achieved Through International Collaboration
Due to the species-specific nature of Fcγ receptors, developing this model demanded multidisciplinary expertise in mouse genetics, antibody biology, and human immunology.
The achievement was made possible through an international consortium of leading biopharmaceutical partners, led by genOway, who combined their knowledge to co-develop and co-validate the genO-hFcγR mouse model. Consortium members included genOway (France), a company specializing in developing highly predictive preclinical models; argenx (Belgium), a pioneer in Fc-engineering and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University (Belgium), a leading immunology institute, to publish the study in Science Immunology. In this study, scientists at VIB-Ghent University mapped Fc receptor expression and regulation to illustrate how the new mouse model could be used to better model human disease and coordinated the publication of the work.
A Unique Solution Available for the Scientific Community
The genO–hFcγR model builds on a previous mouse model developed in 2008 by genOway and its scientific partners, in which multiple FcγR genes were humanized. Since its launch to the scientific community in 2024, genO-hFcγR has been adopted to advance preclinical programs of biopharmaceutical companies and nonprofit organizations, including the Gates Foundation, as one of the foundation's global health research initiatives.
Read the Gates Foundation press release at https://www.genoway.com/news-events/genoway-gates-foundation-2025
About genOway
genOway is a biotechnology company that provides highly predictive preclinical models and solutions to biopharmaceutical companies, CROs and academic institutions to bridge the gap between preclinical findings and clinical success. More information at genoway.com.
Contact
Ana REZA
Marketing Communications Manager
reza@genoway.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
